A cancer drug target already being investigated in clinical trials turns out to be doing something even more consequential than researchers realized.
Pol theta enzyme identified as key driver of cancer resilience
Researchers discovered that the DNA polymerase theta (Pol theta) enzyme, a target in oncology drug trials, inadvertently enhances cancer cell resilience by enabling efficient DNA repair mechanisms. This finding affects clinical trials and cancer treatment protocols, potentially undermining therapeutic efficacy and patient outcomes.